Seventh edition of the National Formulary of India released and Biovigilance Programme of India approved

National Health Health & Medicine

Seventh edition of the National Formulary of India released and Biovigilance Programme of India approved

21 September 2026

Minister of State for Health Anupriya Patel launched the 7th Edition of the National Formulary of India (NFI) on 21 September 2026 in New Delhi.
She also released a guidance document on reporting medical device-related adverse events and the ADR-PvPI 2.0 mobile app for iOS users.
The launch was at the 6th National Pharmacovigilance Week (17–23 September 2026), organised by the Indian Pharmacopoeia Commission (IPC).
She announced that the Government of India has approved the Biovigilance Programme of India, covering medicines and biological products used in organ and tissue transplantation.
She said India rose from 123rd position during 2009-2014 to 8th globally in contributions to the WHO patient safety database.

NFI edition: 7th Pharmacovigilance Week: 6th, 17–23 September 2026 India in WHO safety database contributions: 8th

Why it matters for exams: Drug safety programmes (PvPI, MvPI and now biovigilance) and the role of the Indian Pharmacopoeia Commission are asked in health and governance papers.

Kerala PSCUPSC

21 September 2026 Source: Press Information Bureau (Ministry of Health and Family Welfare)

In plain words

NFI National Formulary of India — A reference book guiding doctors and pharmacists on the rational use of medicines.

PvPI Pharmacovigilance Programme of India — The national programme that collects and analyses reports of adverse drug reactions.

IPC Indian Pharmacopoeia Commission — The body that sets standards for medicines in India.